SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-185076
Filing Date
2023-07-11
Accepted
2023-07-11 09:37:29
Documents
13
Period of Report
2023-07-10
Items
Item 1.03: Bankruptcy or Receivership
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d514612d8k.htm   iXBRL 8-K 36979
2 EX-99.1 d514612dex991.htm EX-99.1 480229
  Complete submission text file 0001193125-23-185076.txt   751624

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvsq-20230710.xsd EX-101.SCH 2537
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvsq-20230710_lab.xml EX-101.LAB 17974
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvsq-20230710_pre.xml EX-101.PRE 11256
7 EXTRACTED XBRL INSTANCE DOCUMENT d514612d8k_htm.xml XML 3507
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 231081328
SIC: 2834 Pharmaceutical Preparations